Causes of Dilatation of the Ascending Aorta
In patients with aortic dilatation, the aortic wall can be weakened by cystic media degeneration. The media displays loss of smooth muscle cells and fragmentation of elastic fibers with the appearance of cystic spaces filled with mucoid material. 4 This normally occurs with aging. The normal growth rate of the aorta is about 0.07 to 0.2 cm/y 5 but can be accelerated by hypertension. At younger ages, cystic media necrosis is associated with various connective tissue diseases such as MFS caused by a mutation in the gene for fibrillin-1, Ehlers-Danlos syndrome type IV with a deficiency in type III collagen, and familial/thoracic aortic aneurysm and dissection, 4 in which genetic heterogeneity is observed. The Loeys-Dietz syndrome (LDS) 6 -8 is a recently recognized syndrome with a difficult phenotype characterized by the triad of arterial tortuosity and aneurysms, hypertelorism, and bifid uvula or cleft palate. Two types can be distinguished. LDS type 1 has many overlapping features with MFS, whereas LDS type 2 has features that overlap with Ehlers-Danlos syndrome. Transforming growth factor-␤ receptor genes (TGFBR1 and TGFBR2) are the only genes known to be associated with LDS. However, no differences in phenotype are found between individuals with TGFBR1 or TGFBR2 mutations, and mutations in these 2 genes are also described in patients with MFS (diagnosed by the Ghent criteria) or with familial/thoracic aortic aneurysm and dissection. LDS is more aggressive than MFS or familial/thoracic aortic aneurysm and dissection with a propensity toward rupture and dissection of the ascending aorta at a younger age and at smaller aortic diameters. [7] [8] [9] On the other hand, LDS patients appear to tolerate surgical intervention well, better than patients with Ehlers-Danlos syndrome IV, because they do not have friable vascular tissue. 9 With respect to histology, the changes in the ascending aorta cannot be distinguished from the cystic media degeneration occurring during aging. However, in individuals with MFS, a marked excess of aortic wall collagen is observed compared with age-matched control subjects. In individuals with TGFBR2 mutation, for instance, this collagen excess is even more accentuated. 6 There is growing evidence that many patients with bicuspid aortic valve (BAV) or aortic coarctation have disorders of vascular connective tissue as well, involving loss of elastic tissue. 10 The aortic expansion rate is higher in patients with BAV than in patients with tricuspid aortic valve: 0.19 versus 0.13 cm/y. 11, 12 This may result in dilatation of the aortic root or ascending aorta, even in the absence of hemodynamically significant aortic valve stenosis or regurgitation. 11, 13 Patients with aortic dilatation and BAV have a greater risk of rupture, dissection, or death than those without BAV. 12 Aortic dilatation and aortic dissection may still occur in this circumstance, even after aortic valve replacement. 13 This confirms a common pathogenetic mechanism for BAV and aortic dilatation that is independent of hemodynamic alterations.
Besides connective tissue disease, hypertension is strongly correlated to aortic dilatation by elevating wall stress. Atherosclerosis, on the contrary, more often causes aneurysms of the descending aorta, particularly aneurysms of the abdominal aorta, not the ascending aorta. 11, 14 Aneurysm formation can also be caused by chronic dissection, trauma, aortic surgery (false aneurysm), and cardiopulmonary resuscitation. Lastly, aortic dilatation can be caused by inflammatory diseases as bacterial or fungal aortitis, Takayasu arteritis, and giant cell arteritis.
When Can Aortic Dissection Occur?
Aortic dilatation may lead to aortic dissection or aortic rupture. The chance of aortic dissection is related to the aortic diameter. In 2002, Davies et al 15 identified that the median aortic diameter at the time of rupture for the ascending or aortic arch was 6.0 cm. There is, however, growing evidence that a substantial number of patients have aortic diameters Ͻ5.5 cm at the time of dissection. Fifteen percent of MFS patients have aortic dissection at a size Ͻ5.0 cm. 16 In the work by Svensson et al, 16 12.5% (5 of 40) of BAV patients had also diameters Ͻ5 cm at the time of operation for aortic dissection. In the analysis by Parish et al, 17 42% (74 of 177) of the non-MFS tricuspid aortic valve patients had a diameter Ͻ5 cm at moment of type A dissection. In the International Registry of Acute Aortic Dissections, nearly 60% of the 591 type A dissection patients had diameters Ͻ5.5 cm, and 40% had diameters Ͻ5.0 cm. 18 Given these facts, aortic diameter alone is not sufficient to explain aortic dissection, and there is a need for additional risk markers. Aortic elasticity has been identified as an additional risk factor for aortic dissection. 19 Whether this has implications for management has to be determined.
When Is Operation Indicated in Asymptomatic Patients? What Do the Guidelines Say?
Until recently, the general agreement was that prophylactic replacement of the aortic root should be performed at a diameter of 5.5 cm in patients with MFS. 20, 21 24 all give practically the same recommendations: (1) Repair of the aortic root or replacement of the ascending aorta is indicated if the diameter of the aortic root or the ascending aorta exceeds 5.0 cm or if the rate of increase is Ն0.5 cm/y; (2) in patients undergoing aortic valve replacement, repair of the aortic root or replacement of the ascending aorta is indicated if the diameter is Ͼ4.5 cm; (3) lower thresholds Reprinted with permission (modified) from Erbel et al 2 for the ESC task force. Note that computed tomography or magnetic resonance measures the external diameter and is expected to be 0.2 to 0.4 cm larger than the TTE/transesophageal echocardiography (TEE) internal diameter. 3 For younger patients, we refer to the nomograms of normal values with SDs related to body surface area in the same article. 2 may be considered for patients of small stature 22 ; and (4) prepregnancy counseling is advised at 4.0/4.5 cm.
Very recently, the 2010 ACC Foundation/AHA guidelines for the management of thoracic aortic disease were published. 3 They recommend similar thresholds for surgery. What is new is the statement that for patients with LDS or confirmed TGFBR1 or TGFBR2 mutation, it is reasonable to undergo aortic repair when the aorta diameter exceeds 4.5 cm.
Given the recent data on type A dissection at diameters Ͻ5.0 cm, the lowered operative risk in large surgical centers, and the current possibilities of valve-sparing surgery, operative treatment at a diameter of Ն4.5 cm may be advised in some cases of connective tissue disease, especially when pregnancy is desired, when there is a family history of dissection, or when there is an indication for elective aortic valve replacement 11, 13, 16, 17, [22] [23] [24] [25] (see Table 2 ). Replacement of the aortic root has also been suggested starting from 4.0 cm in LDS (in particular, when the valve can be spared) [7] [8] [9] and when there is an indication for elective aortic valve replacement. 11 The recent 2010 ACC Foundation/AHA guidelines 3 have provided us with the needed set of adjusted indications for prophylactic surgery of dilated ascending aorta.
Management and Follow-Up in Patients With Aortic Dilatation
In case of dilatation of the ascending aorta Ͼ4.0 cm, evaluation of a possible connective tissue disease should be performed by a multidisciplinary team (cardiologist, geneticist, and ophthalmologist). Patient and family history should be investigated; physical examination should be undertaken; and eventually DNA testing should be carried out. Transthoracic echocardiography (TTE) should be performed to examine the aortic valve and to quantify aortic regurgitation. The diameter of the ascending aorta should be measured at 4 levels: at the level of the annulus, the aortic sinuses, the sinotubular junction, and the proximal ascending aorta. In addition, magnetic resonance imaging or computed tomography should be performed to visualize the entire aorta. 26, 27 Especially in BAV patients, aneurysms tend to occur more frequently in the proximal ascending aorta, which may be difficult to visualize by TTE. Risk factors such as hypertension, cigarette smoking, and hypercholesterolemia should be managed. Blood pressure should be lowered to Յ120/ 80 mm Hg. Currently, ␤-blockers are still the preferred medical therapy, 5, 11, 28 but large prospective multicenter trials of the effects of angiotensin II receptor antagonists or angiotensin-converting enzyme inhibitors on aortic growth in patients with MFS are being performed worldwide. 5, 11 Moderate restriction of physical activity should be advised. 2, 5 Patients should avoid exertion at maximal capacity and specifically should not engage in competitive, contact, or isometric sports. 29, 30 Yearly follow-up of the aortic diameter by TTE and/or magnetic resonance imaging or computed tomography should be performed. In case of LDS, magnetic resonance imaging of the thoracic and cervical vessels should be performed more frequently. Patients with LDS often have a more widespread and malignant course of aneurysmal disease.
Operative Treatment
The aortic valve and ascending aorta are replaced simultaneously by use of a so-called composite valve graft with reimplantation of the coronary ostia into the prosthesis. The most frequent cause of late death is aneurysmal formation at the downstream aorta. Valve-sparing aortic root replacements are becoming more popular in view of the potential thromboembolic, infectious, and bleeding complications after composite graft replacement. In the remodeling technique described by Sarsam and Yacoub, 31 the graft is sewn to the remaining aortic wall around the commissures. This creates neosinuses and leaves the annulus mobile but unsupported. In the reimplantation technique, 32 the graft is fixed at the subannular level, and the valve and commissures are reimplanted inside the fabric. Both procedures offer a reasonable alternative to composite valve grafting with excellent shortand medium-term results, but long-term durability is not yet established.
Genetic Counseling
Most connective tissue disorders, including LDS, are inherited in an autosomal-dominant manner, which means that first-degree relatives are at a 50% risk of inheriting the disease, although the severity cannot be predicted. Firstdegree relatives should therefore be evaluated for manifestations of connective tissue disorder, including a comprehensive clinical examination and TTE. If a disease-causing mutation in the index patient is known, molecular genetic testing of family members is possible, and prenatal testing can be performed.
Conclusions
The clinician should be aware of the need for an aggressive preventive approach in patients with aortic dilatation, specif- ically in cases of a connective tissue disorder. As a result of recent insights, criteria for operative treatment of aortic dilatation have been liberalized in the relevant guidelines. Furthermore, the clinician should realize that first-degree relatives of patients with thoracic aortic dilatation are also at risk and should be evaluated for manifestations of connective tissue disorders.
Follow-Up of Our Patient
For our patient, we decided to operate at 4.6 cm because of the clear family history of aortic dissection, even though ESC guidelines recommend waiting until 5.0 cm. 2 We replaced the ascending aorta prophylactically. A supracoronary replacement of the ascending aorta and proximal aortic arch was performed. A free-floating extension of the arch prosthesis, a so-called elephant trunk, was left behind in the proximal descending aorta for an eventually needed operation of the descending aorta. Histopathological examination revealed extensive media degeneration with fragmentation of elastic fibers ( Figure 2 ) without signs of aortitis. Physical examination at clinical genetic evaluation showed a bifid uvula ( Figure 3 ) but no other outward clinical signs of LDS. A possible pathogenic mutation (c.1043GϾA, p.Cys348Tyr) was found in the TGFBR1 gene. This missense mutation has not been reported previously but is likely pathogenic because it occurs in a strongly conserved amino acid sequence. Family screening and functional studies are underway to confirm the pathogenicity of the mutation.
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